Literature DB >> 4054207

Plasma protein binding of dipyrone metabolites in man.

E Zylber-Katz, L Granit, M Levy.   

Abstract

Four metabolites of dipyrone, 4-methylaminoantipyrine (MAA), 4-aminoantipyrine (AA), 4-formylaminoantipyrine (FAA) and 4-acetylaminoantipyrine (AAA) can be identified in human plasma after its oral administration. The plasma protein binding of the metabolites in samples from 20 healthy volunteers was determined by ultrafiltration. None of the metabolites were found to be extensively bound to plasma proteins. The binding of MAA and AA was relatively higher than of FAA and AAA, as expected from their chemical structure. The mean percentage plasma protein binding was 57.6% for MAA, 47.9 for AA, 17.8 for FAA and 14.2% for AAA. The correlation between the unbound concentration in plasma and the total concentrations of MAA, AA, FAA and AAA was linear. No association was evident between the total protein plasma concentration and the extent of binding. The possible therapeutic implications related to protein binding of several analgesic and non-steroidal anti-inflammatory drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4054207     DOI: 10.1007/BF00547371

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

2.  Protein binding of salicylate in uremic and normal plasma.

Authors:  O Borgå; I O Cederlöf; V A Ringberger; A Norlin
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  The aspirin-ibuprofen interaction in rheumatoid arthritis.

Authors:  D M Grennan; D G Ferry; M E Ashworth; R E Kenny; M Mackinnon
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

Review 4.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

5.  Interactions of aspirin with nonsteroidal antiinflammatory drugs in man.

Authors:  A Rubin; B E Rodda; P Warrick; C M Gruber; A S Ridolfo
Journal:  Arthritis Rheum       Date:  1973 Sep-Oct

6.  The binding of salicylic acid and acetylsalicylic acid to human serum albumin.

Authors:  E Kramer; J I Routh
Journal:  Clin Biochem       Date:  1973-06       Impact factor: 3.281

7.  Naproxen-aspirin interactions in man.

Authors:  E J Segre; M Chaplin; E Forchielli; R Runkel; H Sevelius
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

8.  Simultaneous determination of dipyrone metabolites in plasma by high-performance liquid chromatography.

Authors:  E Z Katz; L Granit; D E Drayer; M Levy
Journal:  J Chromatogr       Date:  1984-02-10

9.  Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels.

Authors:  W D Wosilait
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

10.  The binding of ibuprofen to plasma proteins.

Authors:  L Aarons; D M Grennan; M Siddiqui
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  10 in total

1.  Influence of food on the pharmacokinetics of dipyrone.

Authors:  D Flusser; E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report.

Authors:  Benedict Morath; K Green; M Zaradzki; J Heid; M Karck; T Hoppe-Tichy
Journal:  Eur J Clin Pharmacol       Date:  2018-01-23       Impact factor: 2.953

4.  Formation and excretion of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 6.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 7.  Haematological effects of non-narcotic analgesics.

Authors:  P A Miescher; W Pola
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Effect of age on the pharmacokinetics of dipyrone.

Authors:  E Zylber-Katz; L Granit; J Stessman; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.

Authors:  V Vlahov; M Badian; M Verho; N Bacracheva
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole.

Authors:  Adriana Ariza; Elena García-Martín; María Salas; María I Montañez; Cristobalina Mayorga; Natalia Blanca-Lopez; Inmaculada Andreu; James Perkins; Miguel Blanca; José A G Agúndez; María J Torres
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.